Policy

The fund focus on the investment in the foreign mutual fund “Baillie Gifford Worldwide Health Innovation Fund - Class B USD Shares” (Master fund) managed by Baillie Gifford Investment Management (Europe) Limited. The Master Fund is a UCITS Fund , set up under Ireland law . The Master Fund aims to produce capital growth over the long term. The investment policy is to invest mainly in global equities selected from companies involved in the healthcare industry and which are innovative in their focus on areas such as diagnostics, treatment and prevention. Investment will be concentrated by the number of stocks held but diversified across a range of healthcare themes. The Master Fund will not be restricted to equity securities in the healthcare sector. Equities shall principally be listed, traded or dealt in on one or more of the Regulated Markets worldwide which may be of small, medium or large market capitalization with strong growth potential are selected on an individual stock selection basis by a team of portfolio managers. Investments in Emerging Market Countries may be acquired subject to a limit of 50 per cent. of the Net Asset Value of the Fund. The Fund will have an average net exposure in investment units of the Master Fund, in an accounting year equal to or more than 80 % of the Fund’s NAV and resulting in having an average net exposure related to foreign country risks in an accounting year not less than 80% of the Fund’s NAV. The Fund may invest in derivatives for a purpose of efficient portfolio management or hedging and may invest in derivatives for hedging foreign exchange, as deemed appropriate to a current situation of investment, which shall be subject to the discretion of fund manager.

Fund Type

ForeignInvestment Funds

Sub Type of Fund

Equity Fund

Registered Fund Capital

3,000 Million Baht

Fund Registration Date

29 Jun 2021

Maturity Date

N/A